Cannabis Cannabinoid Guide

Cannabinoids are compounds found in cannabis. THC and CBD are the best known, but a lab report may list several others. Each has its own chemistry, and the amount in a product matters. A cannabinoid's name alone cannot tell you how a product will feel or whether it will help a particular condition.

This guide explains the compounds you are likely to encounter on labels and in research. It is educational, not a treatment or dosing guide. Findings from cells or animals are identified as early research, and results from one formulation should not be assumed to apply to every product containing the same cannabinoid.

The endocannabinoid system

Your body makes its own cannabinoid signals, called endocannabinoids. Along with receptors and the enzymes that make and break down these signals, they help regulate functions such as appetite, pain, and mood. CB1 receptors are especially important in the brain; CB2 receptors are closely associated with immune function. Plant cannabinoids interact with this system in different ways, and some also act at other targets.

For an overview of cannabinoid research and its limits, see NCCIH's cannabis and cannabinoids guide.

Read our Endocannabinoid System Guide for more about the body's cannabinoid signals and receptors.

THC (delta-9-tetrahydrocannabinol)

When a label says THC without specifying an isomer, it usually means delta-9 THC, the main source of cannabis intoxication.

Where it occurs: In cannabis flower and products made from it. Much of the THC available from raw flower starts as THCA and forms when the flower is heated.
Intoxication: THC can alter perception and impair memory, attention, and coordination. It can also cause anxiety.
What research shows: Some THC-containing medicines have evidence for specific uses, including chemotherapy-related nausea. Benefits and adverse effects depend on the preparation and condition studied. NCCIH reviews the evidence.
Key limitations: A higher THC percentage does not establish greater medical benefit. Findings for a standardized medicine do not establish that a retail flower, edible, or concentrate will give the same result.

THCA (tetrahydrocannabinolic acid)

THCA is the acidic precursor to THC. The distinction matters when reading a flower label.

Where it occurs: Often abundant in raw, THC-producing flower. Heat converts it to THC through decarboxylation.
Intoxication: Unheated THCA is generally considered non-intoxicating. Smoking or vaporizing a THCA-rich product produces THC, so the product can be intoxicating when used that way.
What research shows: A cell and mouse study examined effects on pathways involved in nerve-cell injury and inflammation. These are preclinical findings, not proof of benefit in people.
Key limitations: THCA's therapeutic effects in people remain uncertain. A THCA label should not be read as a promise that the product will remain non-intoxicating after heating.

CBD (cannabidiol)

CBD does not produce THC's characteristic high, but it can still have effects and interact with medicines.

Where it occurs: In CBD-producing cannabis varieties and products such as extracts and isolates. Its acidic precursor is CBDA.
Intoxication: CBD itself is non-intoxicating. A CBD-labeled product may also contain THC, so its full composition matters.
What research shows: A purified prescription CBD medicine is FDA-approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. That approval applies to the medicine and its specified uses. FDA discusses CBD research and safety.
Key limitations: CBD can affect other medicines and cause liver injury. Evidence for a prescription product does not validate every retail CBD product or its advertised uses. See FDA's CBD consumer information.

CBDA (cannabidiolic acid)

CBDA is the acidic precursor to CBD. The two compounds should not be treated as interchangeable.

Where it occurs: In raw, CBD-producing cannabis. Heating converts CBDA to CBD.
Intoxication: CBDA is generally considered non-intoxicating. Other ingredients in a product may still cause intoxication.
What research shows: Researchers have studied CBDA in animal models of nausea and vomiting. The results describe effects in rats and shrews, not demonstrated treatment benefits in people.
Key limitations: Human evidence is limited. Research and approvals involving CBD do not establish CBDA's effectiveness or an appropriate dose.

CBG (cannabigerol)

CBG is often called the “mother cannabinoid.” More precisely, its acidic precursor, CBGA, feeds several cannabinoid-producing pathways in the plant.

Where it occurs: Usually a minor component of flower, although some varieties are selected for higher CBG content. Enzyme research documents CBGA's role in forming CBDA.
Intoxication: CBG is generally considered non-intoxicating. A small 2026 human study found few subjective effects after single oral doses.
What research shows: A 2024 trial in 34 healthy adults reported reduced self-rated anxiety after CBG. It was a short study conducted remotely, not a trial of treatment for an anxiety disorder.
Key limitations: Early human findings need confirmation. Small, single-dose studies do not establish long-term safety or effectiveness for a medical condition.

CBN (cannabinol)

CBN forms as THC oxidizes. It is also sold as an ingredient in sleep products.

Where it occurs: In aged or oxidized cannabis and in manufactured cannabinoid formulations. Its presence does not, by itself, predict a product's effects.
Intoxication: CBN is not usually associated with THC's pronounced high, but evidence on its effects in people is still developing. A blend containing THC may be intoxicating.
What research shows: A seven-night trial reported fewer awakenings, but its primary sleep-quality outcome did not significantly improve. A 2026 trial in 20 adults with insomnia found improvements in some measures, but not its primary measure of time awake after falling asleep.
Key limitations: These mixed, short-term findings do not establish CBN as a reliable insomnia treatment. “Contains CBN” is not a guarantee of sedation or better sleep.

CBC (cannabichromene)

CBC is a less-studied plant cannabinoid that may appear in small amounts on a lab report.

Where it occurs: In cannabis and in extracts containing multiple cannabinoids. Its acidic precursor is CBCA.
Intoxication: CBC is generally described as non-intoxicating, although direct human research is limited.
What research shows: A 2023 study in cells and mice found changes in inflammatory activity. It did not test whether CBC treats inflammation in people.
Key limitations: Preclinical findings do not establish a clinical benefit or dose. Studies of blends cannot necessarily identify what CBC contributed.

THCV (tetrahydrocannabivarin)

THCV is chemically related to THC, but the similar name does not mean the two have the same effects.

Where it occurs: In some cannabis varieties, generally at lower levels than THC. It is also sold in concentrated formulations.
Intoxication: THCV was described as nonpsychoactive at the doses used in a small diabetes trial. That does not settle the effects of higher doses or products containing other THC compounds.
What research shows: A 2016 pilot trial in people with type 2 diabetes found changes in some glucose-related measures, but not the primary cholesterol outcome.
Key limitations: A pilot trial does not establish THCV as a diabetes or weight-loss treatment. Claims of dependable appetite suppression or a “clearer high” go beyond what this study establishes.

Delta-8 THC

Delta-8 is a THC isomer: it has the same molecular formula as delta-9 THC, with a different arrangement of a chemical bond.

Where it occurs: Naturally present in small amounts. Commercial quantities are commonly made by chemically converting CBD.
Intoxication: Delta-8 THC is intoxicating. Describing it as “milder” does not establish that a particular product is safe or free of impairment.
What research shows: FDA reports adverse events and manufacturing concerns and states that delta-8 products have not been evaluated or approved for safe use in any context.
Key limitations: Chemical conversion can introduce unwanted by-products. Product composition, testing, and local rules matter; a “hemp-derived” label does not establish safety.

Delta-10 THC

Delta-10 is another THC isomer. It is much less studied than delta-9 THC.

Where it occurs: Encountered on labels for manufactured cannabinoid products. Its name should not be taken to mean it is a major constituent of ordinary cannabis flower.
Intoxication: Do not assume a delta-10-labeled product is non-intoxicating. Its effects may also reflect other THC isomers in the formulation.
What research shows: Published work includes analytical methods for distinguishing delta-10 from other cannabinoids. This type of study does not establish a therapeutic use or a predictable experience.
Key limitations: Human evidence is too limited to support dependable claims about potency or “energizing” effects. A product name alone does not verify its contents.

THCP (tetrahydrocannabiphorol)

THCP attracted attention because of its receptor binding in laboratory research. That finding is often overstated in product marketing.

Where it occurs: First isolated in small amounts from cannabis in a 2019 study.
Intoxication: Animal findings suggest THC-like activity. They do not establish a reliable human dose or how an individual will respond.
What research shows: The discovery study found stronger binding to CB1 receptors than delta-9 THC in a laboratory assay and tested activity in mice.
Key limitations: Stronger receptor binding is not the same as being a fixed number of times stronger in people. Human safety, effects, and therapeutic value remain poorly characterized.

Reading cannabinoid labels

Acidic precursors and decarboxylation

Raw flower often contains more THCA or CBDA than THC or CBD. Heating removes part of the acid molecule, converting these precursors into THC or CBD. “Total THC” may therefore include the THC potentially available from THCA, rather than only the THC already present. Check the lab report's definitions before comparing values.

THC/CBD ratios

A 1:1 ratio means equal amounts of THC and CBD; it does not tell you the amount per serving. A serving containing 1 mg of each and one containing 10 mg of each share the same ratio. CBD also should not be assumed to cancel THC's effects: a controlled study of oral THC with a high dose of CBD found stronger effects than THC alone.

Product labels and lab reports

Our Reading Cannabis Lab Reports guide walks through an example certificate of analysis and explains the units and test results.

Read the amounts per serving and per package, not just the cannabinoid names or percentages. A certificate of analysis should identify the tested batch and show which compounds were measured. “Not detected” means below that test's detection limit, not necessarily absolute zero. A cannabinoid test also does not, by itself, confirm that a product was tested for contaminants.

For aromas and terpene profiles, visit the Cannabis Terpene Guide. For short definitions of cannabis products, research terms, and other terminology, see the Cannabis Glossary.